AR070346A1 - Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos - Google Patents
Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicosInfo
- Publication number
- AR070346A1 AR070346A1 ARP090100415A ARP090100415A AR070346A1 AR 070346 A1 AR070346 A1 AR 070346A1 AR P090100415 A ARP090100415 A AR P090100415A AR P090100415 A ARP090100415 A AR P090100415A AR 070346 A1 AR070346 A1 AR 070346A1
- Authority
- AR
- Argentina
- Prior art keywords
- tslpr
- inflammatory
- lymphopyetine
- timica
- stromal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 1: Un compuesto de union que se une específicamente al TSLPR de humano y de cyno, que comprende: al menos una region variable de cadena pesada de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena pesada al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 1, 2, 3, 73, 7, 8, 9, 13, 14, 15, 19, 20, 21, 25, 26, 27, 31, 32, 33, 37, 38, 39, 43, 44 y 45, o una variante de cualquiera de dichas secuencias; o al menos una region variable de cadena liviana de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena liviana al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 4, 5, 6, 74, 10, 11, 12, 16, 17, 18, 22, 23, 24, 28, 29, 30, 34, 35, 36, 40, 41, 42, 46, 47 y 48, o una variante de cualquiera de dichas secuencias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2683308P | 2008-02-07 | 2008-02-07 | |
| US4203008P | 2008-04-03 | 2008-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070346A1 true AR070346A1 (es) | 2010-03-31 |
Family
ID=40622088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100415A AR070346A1 (es) | 2008-02-07 | 2009-02-06 | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8475793B2 (es) |
| EP (1) | EP2250199B1 (es) |
| JP (2) | JP2011511638A (es) |
| CN (1) | CN101986784A (es) |
| AR (1) | AR070346A1 (es) |
| CA (1) | CA2713935C (es) |
| MX (1) | MX2010008688A (es) |
| WO (1) | WO2009100324A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008265128A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| TW201201840A (en) | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| WO2012054438A1 (en) * | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| RU2689528C2 (ru) * | 2013-08-09 | 2019-05-28 | Астеллас Фарма Инк. | Новое антитело к tslp-рецептору человека |
| US9790506B2 (en) | 2013-10-02 | 2017-10-17 | The Regents Of The University Of California | Diagnostic and screening methods for atopic dermatitis |
| KR102495941B1 (ko) | 2013-12-03 | 2023-02-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| RU2701346C1 (ru) * | 2013-12-06 | 2019-09-25 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения |
| AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| EP3347377B1 (en) | 2015-09-09 | 2021-02-17 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| CN108430507B (zh) | 2015-12-18 | 2022-08-02 | 安斯泰来制药株式会社 | 含有抗人tslp受体抗体的药物组合物 |
| BR112018015283B1 (pt) | 2016-01-26 | 2023-09-26 | Intra-Cellular Therapies, Inc | Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central |
| WO2017146011A1 (ja) * | 2016-02-22 | 2017-08-31 | 国立大学法人 千葉大学 | アレルギー性鼻炎の診断用バイオマーカー |
| EP3436016B1 (en) | 2016-03-28 | 2022-04-27 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA3054841A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| KR20200106498A (ko) * | 2018-01-05 | 2020-09-14 | 이뮤넥스트, 인크. | 항-mct1 항체 및 그의 용도 |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| CN114887053A (zh) * | 2019-11-29 | 2022-08-12 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| WO2023028612A2 (en) * | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
| WO2023155132A1 (zh) * | 2022-02-18 | 2023-08-24 | 绍兴守仁医疗健康科技有限公司 | Rac1蛋白单克隆抗体及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2317917T3 (es) | 2000-06-28 | 2009-05-01 | Amgen Inc. | Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas. |
| EP1793856A2 (en) | 2004-08-20 | 2007-06-13 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| BRPI0706530A2 (pt) | 2006-01-13 | 2011-03-29 | Irm Llc | métodos e composições para tratamento de doenças alérgicas |
| AU2008265128A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
-
2009
- 2009-02-06 WO PCT/US2009/033383 patent/WO2009100324A1/en active Application Filing
- 2009-02-06 AR ARP090100415A patent/AR070346A1/es not_active Application Discontinuation
- 2009-02-06 JP JP2010546045A patent/JP2011511638A/ja active Pending
- 2009-02-06 MX MX2010008688A patent/MX2010008688A/es active IP Right Grant
- 2009-02-06 CA CA2713935A patent/CA2713935C/en active Active
- 2009-02-06 CN CN2009801110754A patent/CN101986784A/zh active Pending
- 2009-02-06 US US12/863,839 patent/US8475793B2/en active Active
- 2009-02-06 EP EP09709406.4A patent/EP2250199B1/en active Active
-
2013
- 2013-07-31 JP JP2013158570A patent/JP2013223516A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009100324A1 (en) | 2009-08-13 |
| MX2010008688A (es) | 2010-08-30 |
| CA2713935A1 (en) | 2009-08-13 |
| US8475793B2 (en) | 2013-07-02 |
| US20110020369A1 (en) | 2011-01-27 |
| CA2713935C (en) | 2016-11-01 |
| EP2250199B1 (en) | 2015-09-02 |
| JP2013223516A (ja) | 2013-10-31 |
| CN101986784A (zh) | 2011-03-16 |
| EP2250199A1 (en) | 2010-11-17 |
| JP2011511638A (ja) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CR20130351A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819) | |
| AR118605A2 (es) | Composiciones anti-cgrp y sus usos | |
| EA201070596A1 (ru) | Гуманизированные антитела против tl1a | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| EA200802168A1 (ru) | Гуманизированное антитело к с-kit | |
| PE20110382A1 (es) | Tratamiento de enfermedad autoinmunitaria e inflamatoria | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| EA201070585A1 (ru) | Композиции, содержащие антитела к vegf, и способы | |
| ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |